The Financial Implications of the Obesity Boom

This chapter discusses the rising costs of obesity treatments and their potential impact on the healthcare system, insurance companies, taxpayers, and Medicare. It explores the coverage limitations of Medicaid for obesity drugs and compares the situation to when Gilead got approval for its hepatitis C drugs.